What's new
Everything that changed here, newest first: research, patents, portfolio works, books, and the site itself.
September 2026
NewResearch & IP
Outcome margin model
Test whether a redesigned care pathway can retain value created through lower cost, better outcomes, or changed risk.
NewResearch & IP
Outcomes acceptance testing
Test whether the intended real world result occurred within stated quality, safety, time, cost, and evidence limits.
NewResearch & IP
Packet workers before execution workers
Start by preparing evidence for a person, then grant narrow action only after review data supports it.
NewResearch & IP
Patient and Caregiver Labor map
Count unpaid calls, forms, portals, travel, record gathering, repeated explanations, and home work around care.
NewResearch & IP
Permissions across linked Eidolons
When one reflection links to another, decide what a reader inherits, what it must request, and what it may never see.
NewResearch & IP
Portfolio decision packet
Put rights, customer value, evidence, cost, observability, and the next commercial action in one review.
NewResearch & IP
Preserve, Amplify, Encode, or Reject
Choose how to handle a claimed differentiated capability after testing what makes it valuable.
NewResearch & IP
Public healthcare opportunity graph
Connect conditions, populations, spending, providers, evidence, products, payment, rights, pathways, and commercial activity.
NewResearch & IP
Public signal evidence ledger
Keep sourced observations separate from calculations, interpretations, AI inferences, hypotheses, and commercial claims.
NewResearch & IP
Recomposition, not replacement
The realistic outcome is not fewer credentialed people. It is credentialed people supervising a distributed set of workers, human and otherwise.
NewResearch & IP
Rights Provenance record for encoded work
Track ownership and permitted use of know how, data, worker contracts, prompts, tests, evidence, and operating records.
NewResearch & IP
Risk bearer map
Show who carries clinical, product, data, implementation, cybersecurity, financial, operational, and reputational risk.
NewResearch & IP
Scarcity migration and half-life review
Review where scarcity sat, where it sits now, and which change will move it next.
NewResearch & IP
Staleness and expiry
Facts age at different speeds. Date them, give the fast ones a review interval, and treat an unreviewed reflection as an unknown rather than a truth.
NewResearch & IP
Technology absorption decision
Choose whether a care organization should build, buy, license, partner for, or consume a technical component.
NewResearch & IP
The business application polypharmacy problem
Applications accumulate the way medications do. Each addition was reasonable at the time; the collection is nobody's deliberate design and nobody's responsibility to review.
NewResearch & IP
The competitor Eidolon evidence line
Mark every competitor claim as observed, disclosed, reported, or inferred, so analysis built on it cannot quietly promote a guess.
NewResearch & IP
The customer Eidolon and its limits
Enough reflection of an account that anyone can prepare before acting, bounded by confidentiality terms, privacy obligations, and contractual restrictions.
NewResearch & IP
The person and the role are two records
Keep a role specification and a person's Eidolon as separate linked objects so work is not written for an office as though it were a personality.
NewResearch & IP
The title trap
A role name hides the scope, authority, evidence, exceptions, and outcomes that determine whether work can move.